| Document |
Document Title |
|
WO/2008/074230A1 |
IFN-alpha mutants are obtained by substituting Cys for Tyr at position 85 or 86 in existing IFN-alpha. Their polyethylene glycol derivatives with high in vitro antiviral activity and prolonged in vivo half-life are also provided, wherein...
|
|
WO/2008/070927A1 |
A soluble multimeric polypeptide or protein is disclosed that is able to inhibit interaction of leukocyte Fcy receptors (FcγR) and immunoglobulin G (IgG). The protein or polypeptide comprises two or more Fc binding regions linked in a h...
|
|
WO/2008/067271A2 |
In an affinity-type purification, ligands dissociated from the stationary phase that would otherwise leach into the species being purified are captured by a second ligand that is also incorporated into the stationary phase, the second li...
|
|
WO/2008/061363A1 |
The present invention relates to monodisperse biomolecule compatible silica particles prepared from organic polyol silanes in the presence of one or more stabilizing entities. The particles may optionally contain detection molecules and/...
|
|
WO/2008/059837A1 |
It is intended to detect, concentrate and purify aflatoxins of all types which are possibly contained in a sample such as a food. It is also intended to detect the total amount or the individual amounts thereof at a high sensitivity. By ...
|
|
WO/2008/058302A1 |
The present invention relates to S-layer protein covered surfaces, wherein the uncovered surface has a biomolecule binding capacity of less than 150 μg/cm2 as measured by the BSA binding test and in that the surface is covered at least ...
|
|
WO/2008/058963A1 |
The invention pertains to the field of membrane protein immobilization onto supports. It relates to a product comprising a support and at least one membrane protein attached to the surface thereof, characterized in that said membrane pro...
|
|
WO/2008/058461A1 |
Exendins or exendin analogs modified by one or more PEG derivatives that may be linked to one or more amino acids of the exendins or exendin analogs are provided. The PEG derivatives may have branched structure set forth in any one of fo...
|
|
WO/2008/052428A1 |
A class of polyethylene glycol-oligopeptide derivative is represented by the following general formula (I): (PEGi Xi )j A ( Fp)q (I), where: i, j, p and q are integers; i=1, 2,…, j; j≥=2; p=1, 2,…, q; q≥=1; PEGi is a polyethylene...
|
|
WO/2008/044957A1 |
The invention relates to molecular biology, in particular to genomics and proteomics, and provides with multi-purpose technique, which makes it possible to detect expressive genes and transcripts and proteins which are encoded thereby an...
|
|
WO/2008/044692A1 |
A novel protein modified so as to attain specific highly efficient linkage of protein via its carboxyl terminal to an immobilization support, having the amino acid sequence of the general formula: R1-R2-R3-R4-R5 wherein the sequence star...
|
|
WO/2008/041767A1 |
[PROBLEMS] To provide: a gene marker or a protein marker for detecting whether or not an Aurora A inhibitor acts in a living body in an Aurora A-specific manner when the Aurora A inhibitor is administered to the living body; and a method...
|
|
WO/2008/040536A1 |
A new method of anchoring a growing peptide chain during chemical synthesis to a solid-phase support is devised. Novel amino acid derivatives and peptide derivatives, both unbonded and bonded to a solid-phase support, are also provided.
|
|
WO/2008/034575A1 |
The iminosugar conjugates having the structural formula (I) with integer n≥0; R1, R2, being chosen from H, OH, NHAc, OGlycosyl, O(CH2)mCH3, or O(CF2)mCF3; R3, R4, R5, and R6 being chosen from H, OH, OGlycosyl, O(CH2)mCH3, or O(CF2)mCF3...
|
|
WO/2008/029281A2 |
Provided in certain embodiments are new methods for forming azido modified biomolecule conjugates of reporter molecules, carrier molecules or solid support. In other embodiments are provided methods for enzymatically labeling a biomolecu...
|
|
WO/2008/028206A2 |
The invention relates to a method for producing reactive monolayer units, characterised in that a multi-functional monolayer-forming component is covalently bonded to a multifunctional carbonyl component comprising an optionally latent c...
|
|
WO/2008/030253A2 |
Disclosed herein is a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolye comprises a composite polypeptide comprising one ...
|
|
WO/2008/025886A1 |
The invention relates to novel chelating agents and metal chelates containing 1,2,3-triazolyl subunits, and their conjugates with biomolecules or particles. The invention concerns also a process for the preparation of the novel chelating...
|
|
WO/2008/025163A1 |
The present invention provides AMPAR excitotoxicity mediating polypeptides comprising the GluR2 NT1 -3-2 (Y142-K172) amino acid sequence (SEQ ID NO:1) or the GAPDH(2-2-1-1) (I221-E250)amino acid sequence (SEQ ID NO:2). Also disclosed are...
|
|
WO/2008/027526A1 |
This invention relates to methods of treating diseases involving accumulation of Aβ plaques, including Alzheimer's Disease by the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of in...
|
|
WO/2008/024300A1 |
The present invention provides methods of treating a subject diagnosed with, or at risk for developing, pathogenic fibrosis, particularly pulmonary fibrosis. The method of the invention comprises administering to the subject a compound o...
|
|
WO/2008/024105A2 |
Nanocomposites of repeat sequence protein polymers and phyllosilicates demonstrated improved material properties, for example, improved elasticity, and are useful as suture, tissue scaffolding, and biodegradable composite materials.
|
|
WO/2008/017483A2 |
This invention discloses novel bacterial spore systems. It has now been found surprisingly that under certain conditions bacterial spore systems can be used in the food and feed industry, preferably in animal feeding and as biohybrid mat...
|
|
WO/2008/019214A1 |
This invention relates to novel protein conjugates, in particular, to novel pegylated proteins, and their methods of making and use. One aspect of the present invention relates to pegylated-erythropoietin having greater clinical efficacy...
|
|
WO/2008/016335A1 |
A process for making a micro-array. The process comprises the step of depositing a population of microbeads on a substrate having at least one fiducial. The population being comprised of at least two sub-populations, preferably multiple ...
|
|
WO/2008/012542A2 |
The present invention relates to a compound which is a polysaccharide derivative of EPO, or of an EPO like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relate...
|
|
WO/2008/012528A1 |
The present invention relates to a composition comprising a population of polysaccharide derivatives of a protein, wherein the protein is insulin or an insulin-like protein and the polysaccharide is anionic and comprises between 2 and 12...
|
|
WO/2008/006189A1 |
Mimotope receptors and inhibitors employ peptide mimics that mimic the shape and function of natural receptors and ligands, thus providing synthetic binding sites for ligands and receptors. Receptor mimics can be attached to carriers, su...
|
|
WO/2007/149490A1 |
This invention provides processes of purifying and recovering trimers of a retroviral envelope (Env) protein from a preparation comprising trimers of the retroviral Env protein and high molecular weight aggregates thereof. Non-ionic dete...
|
|
WO2007109118A9 |
The present invention relates generally to the use of recombinant human CClO (rhCCIO), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of Respiratory Distress Syndrome (RDS), Bronchopulmonary dyspla...
|
|
WO/2007/140768A1 |
The present invention relates to a system of protein binders containing at least one protein binder presented in at least one native form and at least one non-native form and its use including a method for discrimination and/or different...
|
|
WO/2007/140545A1 |
The present invention provides isolated M. tuberculosis protein that is a putative Elongation Factor-Tu (EFTu; SEQ ID NO: 2 or 3) and immunogenic peptide fragments thereof (any one of SEQ ID NOs: 4-83), and antibodies produced against th...
|
|
WO/2007/143161A2 |
Members of the TGF- β superfamily and peptide fragments based on member proteins are employed to purify solutions containing member proteins or as therapeutics.
|
|
WO/2007/139397A1 |
Provided herein are modified OB-fold domains having desired properties; methods of producing libraries of modified OB-fold domains; the libraries of modified OB-fold domains produced by such methods; methods for screening such libraries ...
|
|
WO/2007/132037A1 |
Method for obtaining thymosins and/or the pharmaceutically acceptable salts thereof by means of solid-phase synthesis on polymeric supports, which comprises the steps of linearly synthesizing the thymus-derived peptides in solid phase, i...
|
|
WO/2007/128080A1 |
The present invention relates generally to an assay for molecules which modulate apoptosis, to molecules identified by the assay and to use of the molecules. More particularly, an assay is provided for screening for molecules that intera...
|
|
WO/2007/128550A1 |
The present invention relates to a method of producing a solid coated carrier carrying biological material. Furthermore, the invention relates to a solid coated carrier to which biological material is attached and uses of the solid coate...
|
|
WO/2007/117564A2 |
Combinatorially generated peptides are provided that have binding affinity for clay. The peptides may be used to deliver benefit agents to various clay surfaces.
|
|
WO/2007/108808A1 |
Complementary peptide having at least a sequence complementary to a major immunogenic region of an acetycholine receptor involved in a myasthenia garvis, characterized in that the complementary peptide has at least a sequence SEQ. ID NO1...
|
|
WO/2007/101732A1 |
The invention relates to nucleic acid molecules encoding peptides which interact with autoantibodies associated with glaucoma, to the peptides themselves, to a pharmaceutical composition comprising said nucleic acid molecules and peptide...
|
|
WO/2007/101028A2 |
Methods for recombinant production of functionally active endonucleases by supplementing the cell culture media with Zn++ are provided. Functionally active, recombinantly expressed endonucleases produced in accordance with these methods ...
|
|
WO/2007/097361A1 |
[PROBLEMS] To provide a carrier for immunoglobulin affinity chromatography that simultaneously has high immunoglobulin binding capability and chemical stability and that can be produced at low cost. [MEANS FOR SOLVING PROBLEMS] An immuno...
|
|
WO/2007/097903A2 |
Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9. SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO: 15; and provided is a pharmaceutical composition com...
|
|
WO/2007/095506A1 |
The present invention generally relates to methods of functionalizing proteins, particularly antibodies, at oligosaccharide linkages, methods of humanizing antibodies by modifying glycosylation, as well as to novel antibodies linked to m...
|
|
WO/2007/087679A1 |
The present invention provides isolated M. tuberculosis ribosomal protein S9 (SEQ ID NO: 1) and immunogenic peptide fragments thereof (any one of SEQ ID NOs: 2-7), and antibodies produced against the full-length protein and immunogenic p...
|
|
WO/2007/086619A1 |
A protein, in particular, a modified glycoprotein having an unsaturated functional group introduced into a sugar chain of the glycoprotein is employed in immobilization. More specifically speaking, a protein can be firmly immobilized owi...
|
|
WO/2007/083984A1 |
Provided is a conjugate comprising a pharmacologically active substance covalently bound to a mucoadhesive polymer and a method for transmucosal delivery of a pharmacologically active substance using the same. Specifically, the present i...
|
|
WO/2007/080197A2 |
The invention relate to variant enzymes having one or more mutations with respect to the wild type of said variant enzyme, wherein said mutations selectively spatially orientating the active region of the variant enzyme towards the subst...
|
|
WO/2007/072982A1 |
An object of the present invention is to provide nanoparticles that can easily be delivered to a small site such as a capillary and can be produced using highly biocompatible and safe material. The present invention provides a nanopartic...
|
|
WO/2007/068047A1 |
A soluble multimeric protein or polypeptide is disclosed that is able to inhibit interaction of leukocyte Fcγ receptors (FcγR) and immunoglobulin G (IgG). The protein or polypeptide comprises two or more linked Fc binding regions, at l...
|
